An interventional study of Radiotherapy and Short-course radiotherapy in Rectal Cancer, sponsored by Alexander Valdman. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Alexander Valdman · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.
Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 26th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2025, is one of 20 with no phase, reaches primary completion later than 21 of the 21 other live ones, and was the 59th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Sweden, United States, Canada and 6 more countries
Ages 18+
NanoEcho AB · Sites in Sweden
Ages 18–99 · Healthy volunteers
Skane University Hospital · Sites in Sweden
Ages 18+
Region Skane · Sites in Sweden
Ages 18+
Vastra Gotaland Region · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 11 · Phase 4 1
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 233 across the 40 interventional studies, 142 across the 23 observational. Of the 34 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 64 have an industry lead sponsor. The 10 most frequent:
Alexander Valdman is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Alexander Valdman has 2 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT02669992Karolinska University HospitalLoop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site? | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies in Rectal Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).
The primary aim of this study is to determine whether a combination of CXB + SCRT is non-inferior to CXB + chemoradiotherapy (CRT) regarding the primary endpoint 2-year organ preservation rate. Additionally, we hypothesize that a chemotherapy-free, radiation-only experimental treatment CXB+SCRT is associated with less side-effects compared to the OPERA regime.
In the OPERA trial (Gerard et al, 2023), the CXB was delivered in combination with long-course CRT. A combination of short-course radiotherapy (SCRT) and CXB has previously been used mainly in elderly and comorbid patients not suitable for long-course chemoradiotherapy. Recently, an international multi-institution report showed good outcomes of planned organ preservation using SCRT together with contact brachytherapy boost. However, no randomized data on this combination therapy are available. There are further no trials comparing CRT+CXB and SCRT+CXB.
Study participants will be randomized to either the standard treatment consisting of CXB (90Gy/3 fractions/4 weeks) and CRT 45/50 Gy (1.8/2 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (900 mg/m2 bid, on radiation days) OR the experimental treatment consisting of CXB (90Gy/3 fractions/4 weeks) SCRT (25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contact x-ray brachytherapy (CXB) (90Gy/3 fractions/4 weeks) and chemoradiotherapy (CRT) 45/50 Gy (1.8/2 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (900 mg/m2 bid, on radiation days).
Radiation: Radiotherapy · Radiation: Contact x-ray brachytherapy · Drug: Chemotherapy
Contact x-ray brachytherapy (CXB) (90Gy/3 fractions/4 weeks) and a short-course radiotherapy (SCRT) (25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days).
Radiation: Short-course radiotherapy · Radiation: Contact x-ray brachytherapy
45/50 Gy (1.8/2 Gy/fraction/5 weeks)
25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days
90Gy/3 fractions/4 weeks
Capecitabine (900 mg/m2 bid, on radiation days)
Rectum preservation
Proportion of patients with successful rectum preservation after standard vs experimental treatment. Organ preservation is considered to have failed if the rectum is removed OR if the patient develops non-salvageable locoregional failure
Time frame: At 24 months after start of treatment
Acute treatment-related toxicity
Incidence of grade 3-5 toxicity as assessed by CTCAE v5.0
Time frame: From start of treatment until 90 days after ending treatment
Late treatment related toxicity
Incidence of grade 3-5 toxicity as assessed by CTCAE v5.0
Time frame: From 90 days after ending treatment until end of study
Clinical complete response (cCR)
Proportion of patients with cCR as assessed by DRE, endoscopy, MRI-T2W, and MRI-DWI
Time frame: At 14-16 and 24-26 weeks after start of treatment
Postoperative complications
Difference in postoperative complications (graded according to Clavien-Dindo) after standard vs experimental treatment
Time frame: Within the first 30 days after Total Mesorectal Excision (TME) surgery
Stoma
Proportion of patients with a stoma
Time frame: At 12 and 24 months after start of treatment
Metastasis-free survival
Survival without sign of metastasis after standard vs experimental treatment
Time frame: At 24 months after start of treatment
Locoregional failure
Proportion of patients with locoregional failure after standard vs experimental treatment
Time frame: At 24 months after start of treatment
Overall survival
Overall survival after standard vs experimental treatment
Time frame: At 24 months after start of treatment
TME-free survival
Survival without Total Mesorectal Excision after standard vs experimental treatment
Time frame: At 24 months after start of treatment
Salvage TME resections
Rate of R0 Total Mesorectal Excisions after standard vs experimental treatment
Time frame: From 24 weeks after start of treatment until end of study
Tumor regression grade
Tumor regression grade in the surgical specimen (R0, ypT0, ypTNM) after standard vs experimental treatment
Time frame: After 14-16 weeks and 24-26 weeks after start of treatment
Sphincter preservation
Rate of sphincter preservation after standard vs experimental treatment
Time frame: At 24 months after start of treatment
General Health Related Quality of Life (HR QoL)
General Health Related Quality of Life (HR QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire QLQ-C30. Responses made on a Likert scale are transformed to a score from 0 to 100 where a higher score indicate a better quality of life
Time frame: At baseline and at 3, 6, 12, 24, 36, 48 and 60 months after start of treatment
Colorectal cancer specific Health Related Quality of Life (HR QoL)
Health Related Quality of Life (HR QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) colorectal cancer specific quality of life questionnaire QLQ-CR29. Responses made on a Likert scale are transformed to a score from 0 to 100 where a higher score indicate a better quality of life
Time frame: At baseline and at 3, 6, 12, 24, 36, 48 and 60 months after start of treatment
Bowel function
Bowel function as assessed by the Low Anterior Resection Syndrome (LARS) score. LARS is scored from 0 to 42 points and a higher score indicates worse outcome.
Time frame: At baseline, 3, 6, 12, 24, 36, 48 and 60 months after start of treatment
Plan to share: Yes — Anonymized individual participant data that underlie the reported results.
Supporting information: Study protocol
Time frame: Beginning 9 months and ending 36 months following article publication.
Access criteria: Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by an independent review committee. A data-sharing agreement will also be required. Contact: alexander.valdman@ki.se
Started Mar 2025 (actual). Primary completion is estimated for Apr 2030, 61 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 61 months is above that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexander Valdman